Jasper Therapeutics, Inc. Form 8-K Summary
Reporting date: October 25, 2021; filed October 29, 2021. The filing reports actions under Item 5.02 relating to director compensation and includes the related policy as Exhibit 10.1.
Business Context and Reporting Period
Jasper Therapeutics is a Delaware biotechnology company whose common stock and redeemable warrants trade on Nasdaq under JSPR and JSPRW, respectively. The company is identified as an emerging growth company. This 8-K is not a quarterly or annual financial report.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Material Changes and Director Compensation
On October 25, 2021, the board adopted a non-employee director compensation policy. Annual cash retainers are as follows:
| Position | Annual Retainer |
|---|---|
| Board member, including chairperson | $40,000 |
| Board chairperson additional retainer | $30,000 |
| Audit committee chairperson | $15,000 |
| Audit committee member | $7,500 |
| Compensation committee chairperson | $10,000 |
| Compensation committee member | $5,000 |
| Nominating and corporate governance committee chairperson | $8,000 |
| Nominating and corporate governance committee member | $4,000 |
Retainers accrue quarterly, are prorated for partial service periods, and are paid in arrears within 30 days after each quarter. The company will reimburse reasonable expenses related to board and committee meetings.
Each current non-employee director will receive a one-time stock option covering shares equal to 0.10% of the company’s outstanding capital stock on an as-converted-to-common-stock basis at the grant date. The award will vest in three equal annual installments, subject to continued service, and is expected to be granted after the first applicable Form S-8 registration statement becomes effective.
New non-employee directors will receive the same 0.10% one-time option upon appointment. Continuing non-employee directors will receive an annual option equal to 0.05% of outstanding capital stock on an as-converted basis at each annual meeting, vesting fully on the first anniversary of grant, subject to continued service. All awards fully vest immediately before and contingent upon a change in control, subject to continued service through that event.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or business outlook. The principal potential economic impact is the ongoing cash cost of director retainers and equity dilution or compensation expense associated with stock option awards. The filing does not quantify the number of shares underlying the awards, their exercise prices, or their accounting expense.
Important Facts for Investors to Verify
- Review Exhibit 10.1 for the complete terms of the non-employee director compensation policy.
- Verify the number of shares and exercise prices ultimately issued under the 0.10% and 0.05% option awards.
- Assess the potential dilution and stock-based compensation expense in subsequent financial statements.
- Confirm the effective date and share reserve under the company’s Form S-8 registration statement and 2021 Equity Incentive Plan.
- Review later filings for changes to director compensation, committee assignments, or change-in-control vesting provisions.